Elevated expression of the heparan sulphate proteoglycan glypican-3 (GPC3) was found on mRNA and protein levels in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV, which was established by in vitro selection against mitoxantrone. In order to elucidate a putative role of GPC3 in the drug-resistant phenotype, the mitoxantrone-resistant cell line EPG85-257RNOV was transfected with an expression vector construct carrying an anti-GPC3 hammerhead ribozyme. It could be demonstrated that in anti-GPC3 ribozymetransfected cell clones, the GPC3-specific mRNA and corresponding protein expression levels were decreased to levels that are similar to those observed in nonresistant, parental cells. The anti-GPC3 ribozyme-containing clones reduced the mitoxantrone resistance level up to 21% of the original resistance and the crossresistance against etoposide to 33% of the original value. This reversal of drug resistance was accompanied by an increased cellular mitoxantrone accumulation in the anti-GPC3 ribozymeexpressing cells. In conclusion, it was verified that GPC3 is involved in the cellular protection against mitoxantrone in the atypical multidrug-resistant gastric carcinoma cell line EPG85-257RNOV. Oncogene (2004) 23, 945-955.
Introduction
Simultaneous resistance of tumour cells to multiple cytotoxic drugs (multidrug resistance, MDR) is a major limitation to the successful chemotherapeutic treatment of human malignancies. Owing to the inherent difficulty of studying MDR in vivo, a large number of in vitro models have been developed from different tissue origins and different species. In general, drug-sensitive tumour cell lines were selected in stepwise increasing, sublethal concentrations of a single antitumour agent, and acquired a phenotype of crossresistance to a variety of structurally and functionally unrelated drugs.
Various molecular mechanisms have been associated with MDR in these experimental tumour models. These include enhanced efflux of drugs by the adenosine triphosphate-binding cassette (ABC)-transporter P-glycoprotein (P-gp) (overview in Gottesman et al., 2002; Lage, 2003) . Owing to historical reasons, the P-gpmediatcd MDR is designated as the classical MDR phenotype. In contrast, MDR phenotypes in the absence of P-gp expression are designated as atypical MDR or non-P-gp-mediated MDR. The molecular mechanisms leading to atypical MDR are not fully understood. Consequently, the identification of factors involved in the development of atypical MDR is of urgent importance in order to develop new treatment modalities and improve response rates in advanced cancers. For the purpose of receiving more information about the cellular mechanisms that confer atypical MDR, we previously established an atypical MDR model system derived from the human gastric carcinoma cell line EPG85-257P (257P) by in vitro selection against mitoxantrone (Dietel et al., 1990) .
Previously, it could be demonstrated that this atypical MDR gastric carcinoma cell line EPG85-257RNOV (257RN) shows a vesicular compartmentalization of the antitumour agent accompanied by a decreased cellular drug accumulation (Dietel et al., 1990; . Moreover, it could be demonstrated that in these atypical MDR cells, the expression levels of further members of the ABC-transporter family, 'breast cancer resistance protein' (BCRP) (Ross et al., 1999; and 'transporter associated with antigen presentation' (TAP) (Lage et al., 2001b) , are much more pronounced when compared to the parental cells. In addition, it could be shown that these atypical MDR gastric carcinoma cells show altered DNA topoisomerase IIa (Topo IIa) expression (Kellner et al., 1997) and an elevated expression level of gtypican-3 (GPC3) ) also designated as MXR7 or OCI-5 (Filmus et al., 1988) . However, so far an involvement of GPC3 in the atypical MDR phenotype could not be demonstrated.
Glypicans are a family of heparan sulphate proteoglycans (HSPG) that are linked to the cell surface through a glycosyl-phosphatidylinositol (GPI) anchor (overviews in David, 1993; Bernfield et al., 1999; Perrimon and Bernfield, 2000) . The physiological function of glypicans is still not well understood. However, it could be demonstrated that the GPC3-encoding gene is mutated in patients with the Simpson-Golabi-Behmel syndrome (SGBS) , an X-linked disorder characterized by pre-and postnatal overgrowth and a varying range of dysmorphisms. The clinical features of SGBS suggest that GPC3 is involved in the regulation of cell proliferation and apoptosis during development . In addition, it could be demonstrated in vitro that GPC3 can induce apoptosis or inhibit proliferation in a cell-specific manner (Gonzalez et al., 1998) .
Since transfection of nonresistant gastric carcinoma cells using the GPC3 encoding cDNA was insufficient to confer the atypical multidrug-resistant phenotype , it was suggested that GPC3 alone does not directly induce a drug resistance phenomenon. On the other hand, GPC3 might be an essential part of a multimodal mechanism resulting in atypical MDR. Therefore, inhibition of GPC3 in atypical MDR cells might lead to changes in drug sensitivity.
To test this hypothesis, a specific inhibition of GPC3 was required. Since no low molecular weight pharmaceutical active compounds were described to show a specific GPC3 inhibition, an alternative strategy for GPC3 modulation was applied. Methods for specific and effective modulation of gene expression include the use of antisense oligonucleotides, hammerhead ribozymes, or small interfering RNAs. In contrast to antisense oligonucleotides, hammerhead ribozymes have endoribonuclease activity and are able to cleave a genespecific mRNA sequence (Haseloff and Gerlach, 1988) . Thus, we previously constructed a hammerhead ribozyme (Rz967) directed against the GPC3 encoding mRNA (Wichert et al., 1999) . The in vitro characterization of the anti-GPC3 hammerhead ribozyme Rz967 in a cell-free system revealed a high catalytic activity. Hence, the application of Rz967 in atypical MDR gastric carcinoma cells might result in a decrease of GPC3-encoding mRNA expression level, and as a consequence in the modulation of the atypical MDR phenotype.
Results

Expression of the anti-GPC3 ribozyme Rz967 in gastric carcinoma cells
The human gastric carcinoma cell line 257RN, exhibiting an atypical multidrug-resistant phenotype, was transfected with CMV promoter-driven eukaryotic expression vectors carrying the anti-GPC3 ribozyme Rz967 (Figure 1 ) to make 257RN/Rz cells, carrying Rz967 in antisense orientation related to the promoter to create 257RN/IRz cells, containing a point mutation inactivated ribozyme to generate 257RN/PM controls, or without any insert to establish the 257RN/V control clone. Additional controls were generated by transfection of drug-sensitive, parental cells with the anti-GPC3 ribozyme contruct (257P/Rz). Stable expression of the ribozyme constructs was determined by RT-PCR as exemplified in Figure 2a . Randomly, two independent 257RN/Rz clones, 257RN/Rz clone 1 and 257RN/Rz clone 2, were selected from 13 independent established Rz967-expressing clones for detailed characterization. In contrast, no Rz967 expression could be detected in untransfected gastric carcinoma cells or any of the controls. Analyses of the expression of the control constructs were performed applying the same procedure (data not shown).
Effect of anti-GPC3 ribozyme Rz967 on mRNA expression levels As shown in Figure 2b and c Northern blot analysis demonstrated that in the two clones 257RN/Rz clone 1 and 257RN/Rz clone 2 expressing the anti-GPC3 ribozyme Rz967, the expression level of the GPC3 encoding mRNA was reduced to about 50% of the level in the non-hammerhead ribozyme-transfected, atypical MDR cell line 257RN. This level is comparable to the GPC3 mRNA expression level detected in the nonresistant, parental gastric carcinoma cell line 257P. In contrast, the atypical MDR cell line 257RN and the control transfectants 257RN/IRz showed an unvaried high GPC3 mRNA expression level.
Moreover, Nothern blot analyses revealed that the mRNA expression levels of factors known to be involved in the drug-resistant phenotype, such as BCRP and Topo IIa were not influenced by the ribozyme treatment (data not shown).
Effect of anti-GPC3 ribozyme Rz967on protein expression
In accordance with the observations on the mRNA level. Western blot analysis unambiguously demon- Figure 1 Schematic representation of the hammerhead ribozyme Rz967 directed against the GPC3-encoding mRNA. The cleavage site in the target mRNA is indicated by an arrow, the GUC recognition triplet is underlined. For construction of a noncatalytic active control ribozyme, two point mutations were introduced in the sequence, G 5 -U and A 14 -C. The GPC3 encoding sequence and nt positions were derived from the MXR7 cDNA sequence For control of the equivalence in sample loading, the blot was stripped and rehybridized using a cDNA encoding phosphoglycerate kinase (PGK). (c) Quantification of GPC3 encoding mRNA level from intensities of Northern blot signals using the BioRad molecular analyst software package after normalization against PGK expression level. The relative expression values are means of at least three independent hybridization experiments; error bars show s.d. Figure 3 Effect of GPC3-specific hammerhead ribozyme Rz967 on GPC3 protein expression level measured by Western blot analysis using the mAb K6534 directed against GPC3 in the atypical MDR gastric carcinoma cell line 257RN; the parental, nonresistant cell line 257P; two control clones 257RN/IRz and 257RN/PM; and two independent 257RN-derived clones expressing the anti-GPC3 ribozyme Rz967 (257RN/Rz clone 1 and 257RN/Rz clone 2). For control of the equivalence in protein loading, the blot was stripped and reincubated with a mAb directed against actin
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Colony forming assay
To exclude the possibility that the observed Rz967-dependent modulation of GPC3-specific mRNA expression and reversal of the atypical multidrug-resistant phenotype might be a consequence of unspecific clonal effects or ribozyme expression vector integration, a colony-forming assay was applied using hammerhead ribozyme Rz967 expression vector constructs and the complete panel of controls. Figure 4 demonstrates unambiguously that the viability of neither the original atypical MDR cell line 257RN nor any of the controls (257RN/V, 257RN/PM, 257RN/IRz) was affected by the addition of increasing amounts of mitoxantrone to the tissue culture medium, indicating that the atypical MDR phenotype was not modulated. In contrast, the anti-GPC3 ribozyme Rz967-transfected atypical multidrug-resistant 257RNRz cells rapidly died by mitoxantrone treatment. These results show that application of the anti-GPC3 hammerhead ribozyme Rz967 inhibits GPC3 mRNA expression and, in consequence, reverse the drug-resistant phenotype.
Correlation between GPC3 mRNA expression level and mitoxantrone resistance
For correlation of the GPC3 mRNA expression level and the mitoxantrone-resistant phenotype, 13 independently anti-GPC3 ribozyme Rz967-transfected cell clones (257RN/Rz clone 1-257RN/ clone 13) were characterised with respect to their GPC3 mRNA expression levels by Northern blot analyses (Figures 5a and b) and their sensitivity against mitoxantrone by determination of the IC 50 value using a cell proliferation assay. Figure 6 demonstrates that there is a definite linear correlation (r ¼ 0.87) between the level of GPC3 mRNA expression and the extent of cellular resistance against mitoxantrone.
Accumulation and efflux of mitoxantrone in ribozyme Rz967-transfected cells by flow cytometry
The accumulation of mitoxantrone in nonresistant, parental cells and atypical multidrug-resistant derivatives as well as in anti-GPC3 ribozyme Rz967-containing clones and control transfectants was examined under energy-proficient and energy-deprived conditions by flow cytometry. As shown in Figures 7a-d the drug accumulated in parental 257P cells with consecutive time and increasing mitoxantrone concentrations. The accumulation rate did not differ significantly under energyproficient conditions from that under energy-depleted conditions. Both anti-GPC3 ribozyme Rz967-expressing clones showed mitoxantrone accumulation curves similar to those observed in the nonresistant, parental cell line. In contrast, the atypical MDR cell line 257RN as well as the control transfectants showed extremely little accumulation of the drug. No significant differences under energy-proficient or energy-deprived conditions could be observed in those cell clones, too.
Comparisons of mitoxantrone retention were forestalled by the differences in drug accumulation of the different cell clones (Figures 7e and f) . Thus, the atypical MDR 257RN cells as well as cell clones transfected with control constructs showed an unvarying extremely low a much higher mitoxantrone fluorescence, which did not decrease significantly during the first hour. No significant differences were observed under energy-proficient or energy-depleted conditions, indicating that no active pump mechanism contributes to the modulation of mitoxantrone fluorescence in the anti-GPC3 ribozyme Rz967-treated tumour cell clones.
Competition of glycosaminoglycan side chains
In order to analyse the putative role of the heparansulphate moiety in the GPC3 molecule on cellular drug accumulation, a competition of the glycosaminoglycan side chains of GPC3 was performed using nonresistant, parental cells, atypical multidrug-resistant cell variants as well as anti-GPC3 ribozyme Rz967-containing cells and control clones. As shown in Figure 8 , in the drugresistant gastric carcinoma cell line 257RN as well as in the control clone 257RN/IRz, no influence of heparin, or chondroitin sulphate could be detected. Chondroitin sulphate serves as a control because its structure is similar to heparin, but it does not act as a competitor of the glycosaminoglycan chains. In contrast, both anti-GPC3 ribozyme-treated clones (257RN/Rz clones 1 and 2) and the drug-sensitive, parental cells 257P showed a decreased cellular mitoxantrone accumulation (up to a reduction of 47% of the control in 257RN/Rz clone 2) when treated with heparin prior to mitoxantrone exposure. On addition of chondroitin sulphate, only weak effects could be observed (up to a reduction of 90% of the control in 257RN/Rz clone 2).
Detection of apoptosis
Mitoxantrone triggered apoptosis in atypical MDR cells, anti-GPC3 ribozyme Rz967-treated cells, and drug-sensitive gastric carcinoma cells was measured by flow cytometry following detection of apoptosis-dependent phosphatidylserine (PS) on the outer leaflet of the cytoplasm membrane by incubation with a fluorescenceconjugated anticoagulant and propidium iodide staining. As shown in Figure 9 , the relative induction of apoptotic cells was 7.13-fold increased in the drugsensitive cell line 257P, whereas the appearance of apoptotic cell populations was nearly unaltered in atypical MDR 257RN cells following mitoxantrone exposure, that is 1.37-fold increase of apoptotic cells. Treatment with the anti-GPC3 hammerhead ribozyme Rz967 did not influence the emergence of programmed cell death significantly.
Discussion
Acquired drug resistance phenotype of cell culture models induced by the selection of tumour cells against antineoplastic agents is thought to be a multifactorial event, mediated by a variety of independent interlocked molecular mechanisms. Cell biological and molecular biological analyses of numerous such cell culture models resulted in the identification of various alternative GPC3 and atypical MDR A Wichert et al cellular protection strategies against the attack of cytotoxic compounds, for example, increased expression of ABC transporters. However, the identification of such a mechanism does not exclude the contribution of further important factors to the drug-resistant phenotype. On the contrary, it is of major interest to identify these mechanisms because in the clinical situation, the acquisition of a two-or three-fold drug resistance of a drug-treated cancer can prevent the success of a chemotherapy.
In the previously established and characterized atypical MDR gastric carcinoma cell line 257RN, different drug resistance-associated mechanisms have been identified, including vesicular compartmentalization (Dietel et al., 1990; , enhanced expressions of the ABC transporters BCRP (Ross et al., 1999; and TAP (Lage et al., 2001b) , and alteration in the DNA Topo IIa expression (Kellner et al., 1997) , indicating that the existing drug-resistant phenotype in the gastric carcinoma cell line 257RN is indeed mediated by interaction of different molecular mechanisms. Furthermore, the expression level of the mRNA encoding GPC3 was found to be more pronounced in the atypical MDR cell line 257RN when compared to the nonresistant, parental tumour cell line 257P . This finding indicated that GPC3 might play a role in this atypical MDR phenotype. However, transfection experiments using the full-length GPC3 encoding cDNA and the parental, nonresistant gastric carcinoma cell variant 257P were not sufficient to confer the drugresistant phenotype . There are two potential reasons that could cause this observation: (i) GPC3 may play an essential role in a multifactorial mechanism involved in drug resistance. Overexpression of GPC3 alone cannot confer drug resistance because essential coacting factors are required. In contrast, the specific reduction of GPC3 impairs the putative multifactorial drug resistance mechanism because GPC3 represents an essential factor in this cellular protection strategy. (ii) The applied CMV promoter-driven GPC3 expression system was inadequate to achieve sufficient biological active GPC3 protein that could confer an increased level of drug resistance in the transfected carcinoma cell clones.
In this study, the use of the ribozyme technology was explored to suppress specifically the expression of the GPC3 encoding mRNA and the corresponding protein in the atypical MDR cell line 257RN. The establishment of 257RN-derived cell clones deficient in GPC3 mRNA and protein expression should be a useful tool in the investigation of a putative role of GPC3 in atypical MDR. After realization of this experimental approach, eight major conclusions were derived from this study: (i) a hammerhead ribozyme can be designed and successfully applied to reduce the GPC3 mRNA and protein expression levels in the atypical MDR cell line 257RN to levels that are similar to those observed in non-resistant, parental cells; (ii) the anti-GPC3 ribozyme-mediated suppression of GPC3 mRNA and protein expression is associated with a significant restoration of sensitivity of the tumour cells to the antitumour agents mitoxantrone and etoposide; (iii) in this gastric cancer model the GPC3 mRNA expression level correlates with the degree of drug resistance; (iv) the anti-GPC3 ribozymemediated modulation of the drug-resistant phenotype is accompanied by an increased drug accumulation in these tumour cell clones; (v) competition of the heparansulphate residues of GPC3 in drug-sensitive cells and anti-GPC3 treated clones decreases the cellular mitoxantrone accumulation; (vi) the anti-GPC3 hammerhead ribozyme does not influence an ATP-dependent mitoxantrone export mechanism; (vii) the observed restoration of sensitivity to mitoxantrone and etoposide is not caused by modulation of the already known mechanisms; (viii) thus, we concluded that GPC3 is involved in the cellular protection of the atypical MDR How is it imaginable that GPC3 contributes to drug resistance? GPC3 is a developmentally regulated HSPG that is bound to the cell surface through a GPI anchor (Filmus et al., 1995) . The specific functions of glypicans are still not well understood, but their localization on the cell surface and experimental data indicate that glypicans are involved in the regulation of interactions between growth factors and their receptors (overviews in David, 1993; Bernfield et al., 1999; Perrimon and Bernfield, 2000) . For example, human glypican-1 (GPC1) can stimulate 'heparin-binding' growth factors such as basic fibroblast growth factor (FGF) and growth factor receptor interactions and signalling (Steinfeld et al., 1996) ; or dally, the Drosophila melanogaster homologue to human glypicans, controls cellular responses to decapentaplegic, a TGF (transforming growth factor) b-related morphogen (Jackson et al., 1997) , and can influence signalling mediated by wingless, a member of the Wnt family of growth factors, secreted proteins that control proliferation and differentiation during development (Tsuda et al., 1999) . It has been proposed that GPC3 negatively regulates insulinlike growth factor-II (IGF-II) activity by competing for IGF-II binding with the signalling receptor for IGF-II, IGF-I receptor . This hypothesis was supported by the generation of IGF-II overexpressing mice that displayed skeletal defects that are typical of SGBS (Eggenschwiler et al., 1997) . However, no direct interaction between IGF-II and GPC3 has been detected (Song et al., 1997) , indicating that if GPC3 inhibits IGF-II signalling, it does so by a mechanism that is fundamentally different from that of the known receptor. In conclusion, up to now it is not known as to which growth factors, if there will be any, are regulated by GPC3.
It has been demonstrated that the GPC3 encoding gene is mutated in patients suffering from SGBS , a disorder characterized by pre-and postnatal overgrowth and various visceral and skeletal dysmorphisms. Some of these dysmorphisms could be the result of a deficiency in growth inhibition or programmed cell death. Indeed, it has been demonstrated that GPC3 is able to induce apoptosis in a cellspecific manner (Gonzalez et al., 1998) . So, GPC3 induced programmed cell death in rat mesothelioma and human breast cancer cells, but not in human colon carcinoma cells or murine NIH3T3 fibroblasts.
In addition, it was reported that the expression of GPC3 is commonly silenced in ovarian cancer cells (Lin et al., 1999) , breast cancer cells (Xiang et al., 2001) and malignant mesothelioma cells (Murthy et al., 2000) , indicating that GPC3 functions as a tumour-suppressing factor. On the other hand, it was reported that GPC3 is frequently expressed in colorectal carcinomas (Lage et al., 1998; Filmus and Selleck, 2001 ) and embryonal tumours, such as neuroblastoma, medulloblastoma and Wilms' tumour (Saikali and Sinnet, 2000) . Furthermore, overexpression of GPC3 is a common feature in hepatocellular carcinoma (HCC) (Hsu et al., 1997) .
These authors concluded that GPC3 facilitates tumour cell growth and contributes to tumour cell progression. In contrast to ovarian and breast carcinoma or mesothelioma cells, the impossibility of inducing GPC3-dependent apoptosis in colon cancer cells (Gonzalez et al., 1998) , and the strong GPC3 expression in embryonic small intestine (Filmus et al., 1988) indicate that GPC3 has cell growth facilitating qualities in gastrointestinal-derived carcinoma cells.
In conclusion, the association between mutations in the GPC3 encoding gene and dysmorphism of various organs in SGBS, the indications of tumour suppressing properties of GPC3 and the hints for tumour cell growth supporting qualities of GPC3 suggest a potentially critical role of GPC3 in maintaining the homeostatic balance between cell growth and cell death, which is ultimately the main pharmacological target of cell death inducing antitumour agents, including mitoxantrone and etoposide.
Indeed, it was demonstrated that both antineoplastic agents, mitoxantrone and etoposide, whose crossresistance was reversed by the anti-GPC3 ribozyme Rz967 in the atypical MDR cell line 257RN, achieve their pharmacological effects by interaction with DNA Topo IIa, provoking DNA damage, and, finally, triggering cellular pathways leading to programmed cell death (Walker et al., 1991; Gorczyca et al., 1993) . In contrast to these drug-specific effects, no influence on the considerable crossresistant phenotype was observed by treatment of the cells with the DNA Topo I inhibitor topotecan. Likewise, no modulation of the chemosensitivity against antitumour drugs without significant crossresistance, such as the tubulin inhibitors paclitaxel or vindesine, or alternative DNA-damaging agents like daunorubicin or cisplatin could be observed. In other words, a modulation of the GPC3 mRNA expression level might influence the cellular disposition for triggering drug-specific apoptotic signals. A putative GPC3-mediated antiapoptotic, proviable balance in the atypical MDR gastric carcinoma cells would result in a drug-resistant phenotype. On the other hand, the detection of apoptosis-dependent PS on the outer leaflet of the cytoplasm membrane could not confirm this assumption. The data indicate that GPC3 is not directly involved in anticancer drug-triggered apoptosis.
On the other hand, the increased drug fluorescence measured in the anti-GPC3 treated carcinoma cell clones indicates that GPC3 might be involved in a cellular translocation or distribution mechanism that contributes to the drug-resistant phenotype. This conceivable mechanism might play a role in the perinuclear vesicular drug compartmentalization, which was observed in the atypical MDR cells (Dietel et al., 1990; . However, it was reported from various studies that HSPGs have a putative role in the binding and translocation of hydrophobic molecules (Al-Haideri et al., 1997; Boyd et al., 1998; Mulder and Terwel, 1998; Wells and Blajchman, 1998) . Furthermore, it was reported that HSPGs, such as syndecans and glypicans, are involved in binding, cellular uptake and perinuclear vesicular compartmentalization of a heparin-binding protein (HBP) in endothelial cells, and, as a consequence, in cellular protection from apoptosis (Olofsson et al., 1999) . Whether GPC3 is involved in such a translocation or compartmentalization process of antitumour agents has to be elicited in further investigations.
Competition of, the heparansulphate residues of GPC3 by exposure to heparin showed no effects on high-level GPC3-expressing cell, such as atypical multidrug-resistant 257RN cells and drug-resistant cells treated with a control ribozyme (257RN/IRz). In contrast, in cells with much lower GPC3 expression like drug-sensitive, parental 257P cells and both anti-GPC3 ribozyme-treated clones, a distinct decrease in cellular mitoxantrone accumulation could be observed. This effect might be explained by inhibition of the drug accumulation by heparin or the heparansulphate side, chains of GPC3. Thus, in cell variants exhibiting a low GPC3 expression level, that is, drug-sensitive 257P cells and both anti-GPC3 ribozyme-treated cell clones, there was a high mitoxantrone accumulation, and this accumulation can be inhibited by adding heparin. In drug-resistant 257RN cells with a high GPC3 expression level that consequently have high levels of heparansulphate, mitoxantrone accumulation is already inhibited, and further addition of heparin did not produce any effect. In conclusion, competition of heparansulphate residues by heparin increases the biological effects of GPC3 on the mitoxantrone accumulation rate, indicating that the heparansulphate moiety might be involved in building a cellular barrier for some cytotoxic drugs.
A general experimental problem in performing transfection experiments may occur due to clonal effects, which simulate a biological effect mediated by the transferred cDNA molecule. In this study, five different independent circumstances help to avoid this problem: (i) 13 of 13 independently isolated G418-resistant cell clones expressing the anti-GPC3 ribozyme Rz967 showed a sensitivity to mitoxantrone in a cell proliferation assay, of which two arbitrarily chosen clones were analysed in detail; (ii) none of overall 15 control clones showed any biological effect; (iii) the level of GPC3 mRNA expression correlated with the degree of resistance to mitoxantrone; (iv) in a colony-forming assay anti-GPC3 ribozyme Rz967 transfected cells showed considerable sensitivity as compared to untransfected cells and control transfectants; (v) none of the transfected clones that were derived from the drugsensitive parental gastric carcinoma cells showed any modulation of their chemosensitivity.
The anti-GPC3 ribozyme Rz967, whose kinetic parameters were characterized in a cell-free system previously (Wichert et al., 1999) , demonstrated in this study its biological activity in a cellular system. Although the ribozyme Rz967 was used as a laboratory tool for the elucidation of the relationship between GPC3 mRNA expression level and a drug-resistant phenotype, it may have implications for the reversal of atypical MDR in animals and humans. However, for the clinical application of the ribozyme technology, additional hurdles must be crossed.
Materials and methods
Cell lines and drugs
The establishment and culture of the human gastric carcinoma cell line EPG85-257P (257P) and its atypical MDR variant EPG85-257RNOV (257RN) was described in detail previously (Dietel et al., 1990) . Transfected cell clones were grown under the same conditions and additionally in the presence of 400 mg/ ml G418 (GibcoBRL, Grand Island, NY, USA). The following antineoplastic agents were used: mitoxantrone (Lederle, Wolfratshausen, Germany); etoposide and daunorubicin (Farmitalia Carlo Erba, Freiburg, Germany); cisplatin and paclitaxel (Bristols-Myers, Mu¨nchen, Germany); vindesine (Lilly, Windlesham, UK); and topotecan (SmithKline Beecham, Middlesex, UK).
Construction of a ribozyme and control expression vector systems
In order to obtain cell clones, stable expressing the hammerhead ribozyme Rz967 targeted to GPC3, we used the eukaryotic expression vector pcDNA3.1 (Invitrogen, San Diego, CA, USA). The Rz967 encoding sense and antisense oligonucleotides (Rz967-sense: 5 0 -2-AAAGACTGATGAGT CCGTGAGGACGAAACCAAGCAGT-3 0 ; Rz967-antisense: 5 0 -ACTGCTTGGTTTCGTCCTCACGGACTCATCAGTCT TT-3 0 ) were annealed for 10 min at 721C in the presence of 0.2 U heat-activated Ampli Taq Gold (Perkin Elmer, Foster City, CA, USA) and 10 mM dATP in order to add overchanging A-ends simultaneously, and cloned into the multiple cloning side of the prepared T-tailed pcDNA3.1 vector provided in the eukaryotic TOPO TA Cloning Kit (Invitrogen). The ribozyme Rz 967 contains GPC3-specific antisense flanking regions of 5 and 7 nt on the 5 0 and 3 0 ends of the 22 nt catalytic ribozyme core, which target Rz967 to its cleavage site in 967 nt downstream of the translation initiation site in the GPC3 encoding mRNA sequence. The correct sequence and insertion of Rz967 into the pcDNA3.1 vector was confirmed by dye terminator sequencing with Taq DNA polymerase using an ABI-373 sequencer (Perkin-Elmer).
In order to serve as negative controls, two further expression vectors were constructed as described above with the following modifications: one vector was designed with Rz967 in antisense orientation to the CMV promoter, and the other senseoriented ribozyme insert contains two point mutations, which completely block the ribozyme's cleavage activity (G 5 -U and A 14 -C) (Ruffner et al., 1990) .
Plasmid transfection and confirmation of ribozyme expression
Transfection experiments were performed as described previously (Lage et al., 2001a, b) . Abbreviations for transfected G418-resistant clones were: V, empty expression vector; Rz, Rz967 in sense orientation related to the CMV promoter; IRz, Rz967 in antisense orientation related to the CMV promoter; PM; Rz967 in sense orientation related to the CMV promoter, but containing two point mutations inhibiting the ribozyme's catalytic activity.
The correct expression of the ribozymes was confirmed by RT-PCR with vector-specific oligonucleotide primers: T7-fw 5 0 -TAATACGACTCACTATAGGG-3 0 and BGH-rev 5 0 -TAGAAGGCACAGTCGAGG-3 0 , which yield a 267-bp (257RN/V) or 304-bp (257RN/Rz, 257RN/IRz, 257RN/PM) PCR product. As positive control for each cell line, aldolasespecific primers were used (Ald-fw, 5
0 -GGCAAGGGCATCC TGGCTGCACA-3 0 and Ald-rev, 5 0 -TAACGGGCCAGAA CATTGGCAT-3 0 ) yielding an expected amplification product of 443 bp.
Detection of mRNA expression
The levels of mRNA expression were determined by Northern blot analyses as described previously . Gene-specific hybridization probes were generated by PCR. Oligonucleotide primers were designed after alignment with mRNA sequences of GPC3 , BCRP (Doyle et al., 1998) or Topo IIa (Tsai-Pflugfelder et al., 1988) . Primers used for PCR amplified a 234-bp product for GPC3 (MXR7-fw, 5 0 -TGATGATGGTTAAACCCTGTGG-3 0 ; MXR7-rev, 5 0 -CAATAGTGGTGGTCAGCTTTCCT-3 0 ), a 652-bp product for BCRP (BCRP-fw, 5
0 -GTTTATCCGTGG TGTGTCTGG-3 0 ; BCRP-rev, 5 0 -CTGAGCTATAGAGGCC TGGG-3 0 ), and a 562 bp product for Topo IIa .
Detection of GPC3 protein expression
For the detection of GPC3 core protein, membrane protein extracts were prepared as described earlier (Lage and Dietel, 2002) . Samples of 20 mg of proteins each were loaded onto a 7.5% SDS-PA gel. Separated proteins were transferred on to a 0.2 mm cellulose nitrate membrane (Schleicher and Schuell, Dassel, Germany). To avoid unspecific binding, the filters were incubated in 5% nonfat dry milk, 0.1% Tween-20 in PBS for 3 h. Subsequently, filters were incubated with mouse monoclonal antibody (mAb) K6534 directed against GPC3 (Midorikawa et al., 2002) diluted 1 : 10 000 in the same solution for 2 h and, afterwards, with peroxidase-conjugated mouse antirabbit IgG (1 : 10 000) (Sigma, St Louis, MO, USA; #A-1949). The protein-antibody complexes were visualized by chemoluminescence (ECL system, Amersham) according to the manufacturer's protocol.
Cytotoxicity assay for cell survival
Chemoresistance was tested using a proliferation assay based on sulphorhodamine B (SRB), a protein binding reagent (Skehan et al., 1990) , as described previously (Lage et al., 2001a, b) . The mean values and standard deviations were calculated from multiple, at least three independent experiments for each cell line.
Colony-forming assay
Cells were grown to 50-70% confluence in 80-mm Petri dishes and transfected with hammerhead ribozyme Rz967 expression vector constructs and controls (257RN/Rz, 257RN/IRz, 257RN/PM, 257RN/V). The cells were then split into dishes and grown in medium containing 400 mg/ml G418. About 3 weeks later, cells were treated for 5 days with increasing concentrations of mitoxantrone. After a further 5-day cultivation in the absence of mitoxantrone, cells were stained with 0.2% crystal violet in 10% ethanol, and the visible colonies were counted and compared. The colony number of empty control vector was set to be 100%.
Drug accumulation and efflux assays
The relative cellular accumulation of mitoxantrone was determined by flow cytometry as described previously (Lage et al., 2001b; Kowalski et al., 2002) . To examine efflux of mitoxantrone, the cells were incubated with 10 mg/ml for 1 h as described above. Afterwards, fresh, prewarmed, complete, drug-free medium was added for another 2.5 min to 1 h. Directly after completion of mitoxantrone, accumulation and at several time points after ending incubation, cells were processed and relative intracellular mitoxantrone content was determined.
In order to investigate accumulation and efflux under energy-deprived conditions, 30 min prior to loading the cells with mitoxantrone, the medium was changed to glucose-free, pyruvate-free DMEM (GibcoBRL) containing 5% FCS, plus 10 mM sodium azide to inhibit oxidative phosphorylation, as described elsewhere (Hyafil et al., 1993) . Afterwards, cells were exposed to increasing concentrations of mitoxantrone and incubated in drug-free medium under energy-deprived conditions
Competition of glycosaminoglycan side chains
For investigation of the putative role of the heparansulphate moiety in the GPC3 molecule on drug transport, a competition of the glycosaminoglycan chains of GPC3 was performed as described by others (Song et al., 1997) with some modifications. Briefly, gastric carcinoma-derived cells were incubated for 2 h at 371C in serum-free, drug-free medium containing 255 mM heparin (Sigma, St Louis, USA) mat may act as a competitor of glycosaminogrycan chains present on proteoglycans anchored to the cell surface, or as control in 255 mM chondroitin sulphate (Sigma), which is similar to heparin, but does not act as a glycosaminoglycan competitor. Afterwards, cells were washed, incubated in mitoxantrone-containing medium (10 mg/ml) for one hour and processed as described in the paragraph 'drug accumulation and efflux assays'.
Apoptosis assay
For detection of cytotoxic drug-induced apoptosis, 10 5 cells of each cell tine were seeded in six-well plates in complete medium and allowed to attach overnight. On the next day, gastric cancer cells were incubated with 1 mM mitoxantrone for 72 h. Cells were trypsinized, washed in PBS and incubated with a fluorescence-conjugated anticoagulant (Annexin-V-Fluos; Roche Diagnostics, Mannheim, Germany) detecting PS on the outer leaflet of apoptotic cells and propidium iodide following the manufacturer's recommendations. Stained cells were analysed using an FACScan flow cytometer (Calibur 750, Bcton Dickinson) and Cell-Quest software. The mean values and standard deviations were calculated from three independent experiments in duplicate.
